MAFLD is associated with lower bone mineral density in patients with type 2 diabetes: an exploratory cross-sectional analysis of a potential indirect association with HOMA-IR - Report - MDSpire
Advertisement
MAFLD is associated with lower bone mineral density in patients with type 2 diabetes: an exploratory cross-sectional analysis of a potential indirect association with HOMA-IR
Clinical Report: The Relationship Between MAFLD and Reduced Bone Mineral Density
Overview
This study investigates the association between metabolic dysfunction-associated fatty liver disease (MAFLD) and bone mineral density (BMD) in patients with type 2 diabetes mellitus (T2DM). It finds that MAFLD is significantly associated with lower BMD, with insulin resistance (HOMA-IR) accounting for a modest portion of this relationship.
Background
Type 2 diabetes mellitus (T2DM) is a prevalent chronic condition that can lead to various complications, including osteoporosis and fractures. Recent research suggests that MAFLD, a condition linked to insulin resistance, may adversely affect bone metabolism in T2DM patients. Understanding this relationship is crucial for managing bone health in this population.
Data Highlights
Group
BMD T-score
Prevalence of Osteopenia/Osteoporosis
MAFLD (n=86)
-1.12 ± 1.16
59.0%
Non-MAFLD (n=83)
-0.50 ± 1.07
33.7%
Key Findings
Patients with MAFLD had significantly lower BMD T-scores compared to those without MAFLD (P < 0.001).
Multivariable regression analysis indicated an inverse association between MAFLD and BMD (β = -0.562, P = 0.003).
The indirect effect of MAFLD on BMD through HOMA-IR was statistically significant (β = -0.070, 95% CI: -0.142 to -0.015).
FIB-4 was not independently associated with BMD.
The prevalence of osteopenia/osteoporosis was higher in the MAFLD group (59.0%) compared to the non-MAFLD group (33.7%, P = 0.002).
Clinical Implications
Healthcare professionals should consider screening for MAFLD in patients with T2DM, as it is associated with lower BMD and higher prevalence of osteopenia/osteoporosis. Addressing insulin resistance may be beneficial in managing bone health in this population.
Conclusion
The findings suggest a significant relationship between MAFLD and reduced BMD in T2DM patients, with insulin resistance playing a modest mediating role. Further research is needed to explore the clinical implications of these associations.
